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Background: Despite the development of various systems to generate live recombinant Salmonella Typhimurium
vaccine strains, little work has been performed to systematically evaluate and compare their relative
immunogenicity. Such information would provide invaluable guidance for the future rational design of live
recombinant Salmonella oral vaccines.
Result: To compare vaccine strains encoded with different antigen delivery and expression strategies, a series of
recombinant Salmonella Typhimurium strains were constructed that expressed either the enhanced green
fluorescent protein (EGFP) or a fragment of the hemagglutinin (HA) protein from the H5N1 influenza virus, as
model antigens. The antigens were expressed from the chromosome, from high or low-copy plasmids, or encoded
on a eukaryotic expression plasmid. Antigens were targeted for expression in either the cytoplasm or the outer
membrane. Combinations of strategies were employed to evaluate the efficacy of combined delivery/expression
approaches. After investigating in vitro and in vivo antigen expression, growth and infection abilities; the
immunogenicity of the constructed recombinant Salmonella strains was evaluated in mice. Using the soluble
model antigen EGFP, our results indicated that vaccine strains with high and stable antigen expression exhibited
high B cell responses, whilst eukaryotic expression or colonization with good construct stability was critical for T cell
responses. For the insoluble model antigen HA, an outer membrane expression strategy induced better B cell and
T cell responses than a cytoplasmic strategy. Most notably, the combination of two different expression strategies
did not increase the immune response elicited.
Conclusion: Through systematically evaluating and comparing the immunogenicity of the constructed
recombinant Salmonella strains in mice, we identified their respective advantages and deleterious or synergistic
effects. Different construction strategies were optimally-required for soluble versus insoluble forms of the protein
antigens. If an antigen, such as EGFP, is soluble and expressed at high levels, a low-copy plasmid-cytoplasmic
expression strategy is recommended; since it provokes the highest B cell responses and also induces good T cell
responses. If a T cell response is preferred, a eukaryotic expression plasmid or a chromosome-based,
cytoplasmic-expression strategy is more effective. For insoluble antigens such as HA, an outer membrane
expression strategy is recommended.
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Over recent years, there has been considerable interest in
the use of attenuated Salmonella Typhimurium strains
as live oral vaccines against heterologous antigens or in-
fectious agents [1,2]. Notable advantages to their use in-
clude their ability to induce antigen-specific mucosal,
humoral and cellular responses after infecting the host
via mucosal routes [3-5]. Salmonella strains can be orally
administrated, via food or drinking water, which avoids
the use of injections for vaccine delivery. Furthermore,
vaccine strains may be conveniently and reliably gener-
ated in large quantities by standard cell culture-based
approaches, which considerably lowers the manufactur-
ing costs [6]. Consequently, many different strategies
have been utilized for the development of live recombin-
ant Salmonella oral vaccines against various heterologous
antigens. Some of these approaches utilize episomal
expression systems, where high or low copy plasmids are
used to express heterologous antigen or epitope genes
under the control of various different promoter systems
[7-10]. The antigenic proteins may be retained within the
cell cytoplasm after expression, or may be targeted to cell
surface (outer membrane) of the attenuated Salmonella
strains. For example, the Pneumococcal surface protein A
(PspA) and codon-optimized influenza hemagglutinin
(HA) protein have both been expressed in the cytoplasm
of attenuated Salmonella Typhimurium cells via high
copy plasmids, for use as live oral vaccine candidates
against Streptococcus pneumonia or the H5N1 virus [7,8],
respectively. A high copy ice-nucleation protein (Inp)
derived surface-expressed system was employed to pro-
duce a live recombinant Salmonella oral vaccine against
hepatitis B virus, while a low copy OmpA-derived surface
display system was used to develop a live recombinant
Salmonella oral vaccine against HIV [9,10]. All of these
vaccines were demonstrated to induce strong immune
responses, especially humoral responses. In other studies,
heterologous genes have been expressed in the cyto-
plasm of attenuated Salmonella via chromosome-based
expression cassettes. For instance, a live recombinant
Salmonella strain containing a chromosomally-encoded
SARS-CoV nucleocapsid gene expressed sufficient cyto-
plasmic protein to elicit both humoral and cellular
immune responses against SARS-CoV [11]. Salmonella
has also been employed as a live delivery vector for
eukaryotic expression plasmids harboring antigen genes.
This strategy may avoid problems such as codon bias or
low levels of antigen expression. Using this approach, live
recombinant Salmonella was used to deliver an HA DNA
vaccine against the H9N2 virus, and a VP28 DNA vaccine
against the white spot syndrome virus in crayfish [12,13].
In several reports, two or three different approaches
have been used to construct analogous live recombinant
Salmonella oral vaccines that target the same pathogen,and their respective immunogenicities were subsequently
compared. In studies aimed at developing a live oral Sal-
monella vaccine against Mycoplasma hyopneumoniae,
identical Adh and NrdF antigen genes were expressed
using either plasmid- or chromosome-based systems.
Animal tests suggested that the vaccine strain containing
the chromosome-based expression system induced a
stronger humoral immune response than the one con-
taining the plasmid-based expression system [14]. Simi-
larly, in efforts to construct a live oral Salmonella-HIV
vaccine, the HIV rgp120 antigen was expressed cytoplas-
mically using either a chromosome-based cassette, a high
copy plasmid, or in the outer membrane via an OmpA
expression system. Animal experiments subsequently
revealed that the membrane-expressed HIV antigen was
capable of inducing a better humoral response than the
cytoplasmically-expressed HIV antigen expressed using
the other two expression systems [10].
The enhanced green fluorescent protein (EGFP), origin-
ally isolated from the Aequorea victoria jellyfish, is
an easily expressed, soluble and species-independent
reporter protein, which emits green florescence after
absorbing blue light. Its intracellular expression levels and
location can be conveniently monitored by fluorescence
microscopy, using a fluorescence micro-plate reader, or by
fluorescence-assisted flow cytometry. Furthermore, it has
been reported that it contains a mouse H2-Kd-restricted
CTL epitope, which could elicit a strong immune response
[15]. All of these characteristics suggest that EGFP could
be a good vaccine model antigen in mice [16].
Despite the development of numerous strategies for
the construction of Salmonella vaccine strains, there
have been relatively few studies aimed at systematically
evaluating and comparing their respective immunogenic
properties. Such information would provide invaluable
guidance for the future rational design of live recombin-
ant Salmonella oral vaccines. To directly address this
issue, we construct analogous sets of live recombinant
Salmonella Typhimurium vaccine strains expressing two
model antigens: enhanced green fluorescent protein
(EGFP) and the hemagglutinin epitope (residues 91–261,
HAOP) from H5N1 virus (H5N1 A/Vietnam/1194/2004),
via different commonly used strategies. Through system-
atically evaluating and comparing the immunogenicity of
these strains in mice, we identified their respective advan-
tages, as well as deleterious or synergistic effects. The
construction strategies of recombinant Salmonella vac-
cine strains for various needs and different forms of anti-
gens (soluble or insoluble antigens) were also proposed.
Results
Construction of recombinant Salmonella-EGFP strains
Six ‘single-recombinant’ SL7207-EGFP strains were first
constructed to express the EGFP gene by a single
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respectively (Table 1). Strains HP, LP and CP were each
designed to express EGFP in the cytoplasm of Salmon-
ella from a high copy plasmid, low copy plasmid or
chromosome-based prosseA expression cassette, respect-
ively. Strains HO and CO were designed to express
EGFP on the outer membrane of SL7207 from a high
copy plasmid, or a chromosome-based prosseA-lpp-
ompA outer membrane expression cassette, respectively.
Strain E carried a high-copy eukaryotic expression plas-
mid pEGFP driven by a eukaryotic cmv promoter. Con-
sequently, EGFP would not be expected to be expressed
in significant amounts until pEGFP was released into
cells of the eukaryotic host. HP and HO sub-groups
were constructed by using the high copy number plas-
mid with pUC origin as backbone. These plasmids exist
in about 500–700 copies in one bacterial cell [17]. Low
copy number plasmid sub-group LP was constructed
using p15A origin in the backbone. The plasmid exists
in 10–12 copies per bacterial cell [17]. Chromosome-
based sub-groups CP and CO were constructed by
lambda red recombineering [18] which resulted in only
one copy of EGFP expressing cassette in one bacterial
cell. The high-copy eukaryotic expression plasmid
pEGFP also uses pUC origin as backbone.
Five additional ‘double-recombinant’ Salmonella-EGFP
strains were then constructed, by combining two of the
above strategies (Table 1). Four of them were created
from the chromosome-based EGFP expression strain,
CP. This was achieved by establishing the pHP, pLP,
pHO, or pEGFP plasmids within CP, generating the
double-recombinant CP +HP, CP+LP, CP+HO and
CP+E strains, respectively. The pEGFP plasmid was
transformed into the LP strain to generate a further
double-recombinant strain, E + LP.
In vitro and in vivo EGFP expression of recombinant
Salmonella strains
Detection of EGFP expression and cell morphology of
recombinant Salmonella-EGFP strains
Out of the six ‘single-recombinant’ Salmonella-EGFP
strains, green fluorescence could be directly observed in
cells of the HP, LP, CP and HO strains by fluorescent
microscopic analysis (Figure 1A). Since no fluorescence
was observable for the CO strain, EGFP expression
was confirmed by Western blotting (Figure 1C). This
revealed that the EGFP gene was being translated within
the CO strain. Because EGFP would not be expressed in
significant amounts until pEGFP in strain E was released
into eukaryotic cells, we detected its expression at differ-
ent time points in vitro and in vivo, respectively, using
Western blotting. In vitro, the EGFP expression was
detected by infecting the Caco-2 human colon carcin-
oma cell line with E strain. Figure 1D showed that EGFPcould be successfully delivered into eukaryotic cells by E
strain in vitro, and its expression was found within
the eukaryotic cells at 12, 20 and 30 hours after infec-
tion. Furthermore, the EGFP expression delivered by E
strain was also investigated in mice intestine on day 1, 3
and 7 after inoculation of 1 × 1011 bacterial cells.
Western blotting result (Figure 1E) showed that EGFP
expression was observed in mice intestinal mucosa on
day 1 after inoculation.
Filamentation of bacterial cell (the elongated, rod-like
cell morphology) was clearly observable for the HP, HO
and E strains. Consequently, the average cell lengths for
each of the created strains were determined using the
Image J software package, and were compared with
those of the parent SL7207 strain. It is shown in
Figure 2A that the average lengths of the HP, HO and E
strains were 8.1 μm, 6.0 μm and 5.5 μm, respectively,
which was considerably longer than the average length
of the SL7207 cells, which was 2.5 μm [19].
Levels of EGFP-derived green fluorescence in the five
double-recombinant strains were similarly analyzed by
fluorescence microscopy (Figure 1B). Fluorescence could
be clearly observed for cells of each of the five strains.
With the exception of the CP+LP strain, cells were
highly elongated compared with the SL7207 strain. Ana-
lysis of average cell length using Image J software
(Figure 2A) indicated that cell filamentation of E + LP
strain were the most highly elongated; with an average
length of 15.7 μm. CP+HP, CP +HO and CP+E cells
were also significantly filamented, with average lengths
of 6.2 μm, 3.2 μm and 7.3 μm, respectively.
EGFP expression levels in recombinant Salmonella strains
To quantify EGFP expression levels within the eleven re-
combinant Salmonella-EGFP strains, the intensity of
green fluorescence for 1 × 108 freshly cultured planktonic
cells were determined using a micro-plate reader
(Figure 2B). For the three ‘cytoplasmic expression’
single-recombinant strains (i.e. HP, LP, and CP), there
were clear differences in fluorescence levels. The HP
strain exhibited the highest fluorescence intensity levels
(1.9 × 103 a.u.), followed by LP (5.6 × 102 a.u.), with CP
being barely fluorescent (11 a.u.). For the two
membrane-based expression strains, fluorescence levels
were only significant for the HO strain (68 a.u.), with
the CO strain (2 a.u.) being essentially non-fluorescent;
practically the same as the SL7207 strain (1 a.u.). Fluor-
escence levels for the E strain, which carries the
eukaryotic EGFP-expression plasmid, were similarly neg-
ligible (2 a.u.). These results clearly indicated that the
fluorescence intensities observed within freshly cultured,
planktonic cells were highest for the cytoplasmic-
expression strains, and were also positively correlated to
the plasmid copy numbers. The data also match the
Table 1 Plasmids and strains used in this study
Plasmids Relevant genotype or characteristics Ref. or source
pBluescript II SK AmpR; Cloning vector, pUC origin 500–700 copy per cell Stratagene
pMD18-T AmpR; Cloning vector, pUC origin 500–700 copy per cell Takara
pSim6 AmpR,Lambda-red recombinase plasmid [18]
ploxp-cm-loxp AmpR, CmR ; pBSK derivative containing EGFP and loxp-cm-loxp fragment [57]
pEGFP KmR ; CMV promoter drived EGFP expression, pUC origin 500–700 copy per cell Lab stock
pACYC177 CmR ; p15a origin plasmid, 10–12 copy per cell Lab stock
pVAX-1 KmR ; CMV promoter; pUC origin 500–700 copy per cell Lab stock
pHP AmpR; pBSK derivative containing prosseA promoter, egfp gene This study
pHAOP AmpR; pBSK derivative containing prosseA promoter, ha(91–261) gene This study
pCP-cm AmpR, CmR ; pBSK derivative containing prosseA promoter, egfp gene, and loxp-cm-loxp fragment This study
pLP CmR ; pACYC177 derivative containing prosseA promoter, egfp gene This study
pOmpA AmpR; pMD18-T derivative containing lac promoter, and lpp-ompA gene This study
pHO AmpR; pMD18-T derivative containing lac promoter, and lpp-ompA-egfp gene This study
pO-HAOP AmpR; pMD18-T derivative containing lac promoter, and lpp-ompA-ha(91–261) gene This study
pCO-cm AmpR, CmR ; pBSK derivative containing prosseA promoter, lpp-ompA-egfp gene, and loxp-cm-loxp fragment This study
Strains Relevant genotype or characteristics Ref. or source
S. typhimurium
SL7207 hisG46 DEL407 [aroA::Tn10 {Tcs}]; B. Stocker
HP AmpR; SL7207; with plasmid pHP This study
LP CmR ; SL7207; with plasmid pLP This study
CP CmR ; SL7207; htrA<>prosseA-egfp-cm This study
HO AmpR; SL7207; with plasmid pHO This study
CO CmR ; SL7207; htrA<>prosseA-lpp-ompA-egfp -cm This study
E KmR ; SL7207; with plasmid pEGFP This study
CP+HP CmR ; AmpR; SL7207; CP with plasmid pHP This study
CP+ LP CmR ; SL7207; CP with plasmid pLP This study
CP+HO CmR ; AmpR; SL7207; CP with plasmid pHO This study
CP+ E CmR ; KmR ; SL7207; CP with plasmid pEGFP This study
E + LP CmR ; KmR ; SL7207; LP with plasmid pEGFP This study
C-HAOP AmpR; SL7207; with plasmid pHAOP This study
O-HAOP AmpR; SL7207; with plasmid pO-HAOP This study
BSK AmpR; SL7207; with plasmid pBSK This study
ACYC177 CmR ; SL7207; with plasmid pACYC177 This study
OmpA AmpR; SL7207; with plasmid pOmpA This study
VAX-1 KmR ; SL7207; with plasmid pVAX-1 This study
VAX-1 +ACYC177 CmR ; KmR ; SL7207; with plasmid pVAX-1 and pACYC177 This study
E. coli
DH10B endA1 recA1 galE15 galK16 nupG rpsL ΔlacX4 Φ Φ80lacZΔM15 araD139 Δ(ara,leu)7697 mcrA
Δ(mrr-hsdRMS-mcrBC) λ-
Lab stock
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cence microscopy (Figure 1A). In summary, the EGFP-
expression levels in the six ‘single-recombinant’
Salmonella strains were in the order (highest to lowest):
HP >LP >HO>CP >CO and E (p < 0.01).
The intensities of EGFP fluorescence in the five
‘double-recombinant’ strains were not enhanced, as had
initially been expected (Figure 2B). In contrast, for fourof the five double-recombinant strains, green fluores-
cence intensities were significantly lower than in the
respective single-recombinant parent strains. The fluor-
escence intensity of the CP+HP strain (5.6 × 102 a.u.)
was more than three-fold lower than the parent HP
strain (1.9 × 103 a.u., p < 0.01). The fluorescence of the
CP+HO strain (11 a.u.) was essentially identical to the
CP parent (11 a.u.), and more than 6-fold lower than
Figure 1 Analysis of in vitro and in vivo expression of recombinant Salmonella-EGFP strains. (A) and (B) Representative fluorescence
microscopy images of EGFP antigen expression in six ‘single-recombinant’ Salmonella strains: HP, LP, CP, HO, CO and E (A) and in five
‘double-recombinant’ Salmonella strains: CP +HP, CP+ LP, CP+HO, CP + E and E + LP (B). The SL7207 parent strain was used as a control.
B.F. = bright-field images; MERGE= composite of bright-field and fluorescent images. Scale bar represents 5 μm. (C) Western blot analysis of EGFP
expression in the CO strain. Expression of EGFP protein (theoretical mass ca. 39 kDa) was detected using a GFP rabbit polyclonal IgG. The SL7207
strain was used as a negative control. (D) Western blot analysis of EGFP expression in the Caco-2 human colon carcinoma cell line delivered
by E strain. Expression of EGFP protein (theoretical mass ca. 26 kDa) was detected at 12, 20 and 30 hours after infection using a GFP mouse
monoclonal IgG. The SL7207 strain was used as a negative control. The GAPDH detection was performed as the internal control. (E) Western blot
analysis of EGFP expression in mice intestine mucosa delivered by E strain. EGFP detection was carried out on day 1, 3 and 7 after inoculation.
The SL7207 strain was performed identically as a negative control. The GAPDH was detected as the internal control.
Zheng et al. BMC Immunology 2012, 13:54 Page 5 of 23
http://www.biomedcentral.com/1471-2172/13/54the HO strain (68 a.u., p < 0.01). The EGFP expression
levels for the E+ LP strain (2.3 × 102 a.u.) were less than
half those determined for the LP strain (5.6 × 102 a.u.,
p < 0.01), and the fluorescence of the CP+E strain (3 a.u.)
were almost 4-fold lower than those of the CP strain(p < 0.01). Of these five combinations, only CP+LP
(6.0× 102 a.u.) maintained EGFP fluorescence levels that
were similar to those of the parental strain, LP
(5.6 × 102 a.u.). This indicated that EGFP expression
levels within the double-recombinant Salmonella strains
Figure 2 Cell length measurement and determination of EGFP
expression levels for recombinant Salmonella strains. (A) Cell
length measurements for the eleven recombinant Salmonella strains.
Each bar in the graph represents the mean length of 20 bacterial
cells randomly selected from multiple microscopic fields for each
strain, as measured using Image J software. Error bars show the
standard deviation. An asterisk indicates that the mean length of
the cells were significantly different from those of the SL7207
parent strain, as determined by Student T-test (P< 0.05). (B) Intensity
of EGFP fluorescence emitted by each of the eleven recombinant
Salmonella strains. SL7207 was included as a negative control.
Measurements correspond to the average fluorescence emitted
by 1 × 108 freshly-cultured bacterial cells (in 96-well micro-titer
plates; excitation 488 nm, emission 518 nm); time resolved
fluorescence of 500 ms. Bars in the graph represent the average
fluorescence intensities from three independent experiments,
± standard deviation.
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parental strains; being listed in the following order: CP+
HP, CP+LP>E+LP>CP+HO>CP+E (p< 0.01).
In vitro growth rates of recombinant Salmonella-EGFP strains
In order to investigate whether single and double recom-
binant strategies would affect the growth of recombinantstrains which may further influence bacterial infection
abilities in vivo, the doubling times of the six single and
five double-recombinant Salmonella-EGFP strains were
measured in liquid LB medium supplemented with anti-
biotics in vitro.
Table 2 shows the growth rates of the six single-
recombinant Salmonella-EGFP strains. The doubling
times of the HP, LP, CP, HO, CO and E strains were
33.2 ± 4.0, 39.2 ± 1.5, 44.2 ± 2.6, 38.9 ± 3.0, 52.5 ± 2.6 and
33.0 ± 3.0 minutes, respectively. Their doubling times
were all significantly higher than that of the parental
strain SL7207 (26.3 ± 0.9 min, p < 0.05). Comparing
the six recombinant strains, the growth rate of the
chromosome-based outer-membrane strain CO was
considerably slower than that of the other five strains
(p < 0.01). Furthermore, the growth rates of strains con-
taining high or low copy-EGFP plasmids were also com-
pared with those of strains containing the corresponding
empty vectors. Strains HP and E exhibited similar
growth rates to the strains containing the corresponding
empty vectors BSK (35.0 ± 1.4 min) and VAX-1
(31.2 ± 1.9 min). This indicated that the metabolic burden
associated with maintaining the pBSK and pVAX-1 high
copy plasmids was primarily responsible for the increase
in doubling times for the HP and E strains. The growth
rates of the LP and HO strains were considerably
different to those of the corresponding empty-vector
strains ACYC177 (42.8 ± 1.7 min, p < 0.01) and OmpA
(35.8 ± 1.2 min, p < 0.05). This suggested that both EGFP
expression and plasmid burden affected their growth rates.
The growth rates of five double-recombinant Salmon-
ella-EGFP strains were also measured, and are described
in Table 3. The doubling times of strains CP +HP, CP +
LP, CP +HO, CP+E, E + LP were: 58.3 ± 2.5, 51.0 ± 2.3,
105.9 ± 7.4, 65.7 ± 2.5 and 68.3 ± 9.9 minutes, respect-
ively. These values were considerably higher than the
doubling time of the SL7207 strain (p < 0.01). Also, we
found that their growth rates were significantly slower
than those of the corresponding single-recombinant par-
ental strains (p < 0.01 or p < 0.05; described in Table 3).
The growth rate of strain VAX-1 +ACYC177, which
contains two empty vectors: pVAX-1 and pEGFP, was
measured as a control for the E + LP strain. Experiments
revealed that there were no significant differences in
the growth rates of these two strains. Taken together,
these results indicated that double-recombinant strat-
egies seriously reduced the growth rates of these five
strains comparing to that of strains with single strategies
and SL7207.
In vitro stability of EGFP expression constructs under
antibiotic pressure
To maximize plasmid stability and copy-number within
the recombinant strains, two strategies were used. Firstly,
Table 2 In vitro doubling times of six single-recombinant Salmonella-EGFP strains
Strains SL7207* HP BSK LP(a) ACYC177 CP HO(b) OmpA CO** E VAX-1
DT (min) 26.3 ± 0.9 33.2 ± 4.0 35.0 ± 1.4 39.2 ± 1.5 42.8 ± 1.7 44.2 ± 2.6 38.9 ± 3.0 35.8 ± 1.2 52.5 ± 2.6 33.0 ± 3.0 31.2 ± 1.9
* The doubling time of the SL7207 strain was significantly different from those of the six single-recombinant strains (p < 0.05); ** The doubling time of the CO
strain was significantly increased compared to those of the other five single-recombinant strains (p < 0.01); (a) A significant difference was observed between the
doubling times of the LP strain and the strain containing the corresponding empty vector ACYC177 (p < 0.01); (b) The doubling times of the HO and OmpA strains
are significantly different (p < 0.05).
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mental process. Secondly, all strains were freshly cul-
tured for 10 hours, diluted 1:10 with fresh medium, and
then cultured until the OD600 reached 2 a.u. Immediately
prior to oral administration, the stability of the EGFP
expression constructs within each of the eleven Salmon-
ella-EGFP strains were evaluated using colony forming
unit (CFU) assays.
Table 4 summarizes the results of these assays, which
evaluate the retention of functional antibiotic-resistance gene
cassettes within the six single-recombinant Salmonella-EGFP
strains. Three plasmids (pLP, pHO, pEGFP) and two
chromosome-based expression cassettes (CP and CO
strains) exhibited good stability, with 100.0% survival rate
on the selection plates. However, for the HP strain, only
88.9% of CFUs maintained pHP. This indicated that
EGFP expression in the HP strain may be less stable than
the other strains, thereby possibly affecting its immuno-
genic potency.
Since the reduction in EGFP expression levels for the
five double-recombinant strains may be related to the
relative stability of the two EGFP expression cassettes,
their respective stabilities were also evaluated using CFU
assays, performed immediately prior to oral administra-
tion. It may be seen in Table 5 that both expression cas-
settes were only completely stable (i.e. detected in
100.0% of CFUs) in two of the five double-recombinant
strains: CP+ LP and CP+E. The chromosome-based
EGFP expression cassettes (from the parent CP strain)
as well as the low-copy plasmids (p15A-replicons, in the
LP strains) appeared to be very stable, with a 100.0%
detection rate. However, the high copy plasmids (pUC-
replicons) in the double-recombinant strains were sig-
nificantly less stable. The detection rates for pHP in the
CP +HP strain, pHO in the CP +HO strain, and pEGFP
in the E + LP strain were 0.8%, 60.0% and 50.0%,
respectively. Even though the p15A and pUC-based
plasmids should be entirely compatible within the
double-recombinant E +LP strain (and maintained using
orthogonal antibiotic resistance strategies), the high-
copy plasmid exhibited poorer stability. It may be notedTable 3 In vitro doubling times of five double-recombinant Sa
Strains SL7207** CP+HP(1) CP+ LP(2) C
DT (min) 26.3 ± 0.9 58.3 ± 2.5 51.0 ± 2.3 1
** the doubling time of the SL7207 strain was significantly different from those of f
indicates their doubling times were significantly increased compared to their respethat the relative differences in fluorescence levels between
the single and double-recombinant strains (Figure 2B)
correlates-well with the plasmid stability properties
revealed by the CFU assays (Table 5).
In vivo survival and infection ability of six single-
recombinant Salmonella strains and stability of EGFP
expression constructs
To evaluate the survival and infection abilities of the six
single-recombinant Salmonella-EGFP strains and the
stabilities of the EGFP expression constructs in vivo;
fecal samples, as well as spleen and mesenteric lymph
node samples were collected from each group of mice
on days 1, 3 and 7 after the oral administration of
1 × 1011 bacterial cells, respectively. CFU assays were
carried out using LB agar plates with or without the
appropriate antibiotics. The SL7207 strain was treated
identically as a control.
Enumeration of CFUs in feces [Figure 3A (1)] showed
that 105-109 cfu/g of the Salmonella cells were present
on day one, for the seven administration groups. The CP
strain was present in the highest levels in the feces, with
109 cfu/g (p < 0.01). The stability assays [Figure 3A (2)]
suggested that the chromosome-based expression strains
(CP and CO), as well as the strain with the low copy
plasmid (LP), exhibited good stabilities, with 100.0%
survival rates on the selection plates. However, strains
containing the high copy prokaryotic or eukaryotic plas-
mids: HP, HO and E, appeared to be less stable; with
detection rates of 35.0% (p < 0.01), 90% and 72.2%,
respectively. On day 3, fecal bacterial cells in the seven
administration groups declined to 103-107 cfu/g. The CP
strain still exhibited the best survival ability, with
107 cfu/g (p < 0.01). Regarding the stability of the con-
structs, the CP and CO strains remain good stability, with
100% detection rates on the antibiotic selection plates. But
the low copy plasmid within the LP strain was somewhat
less stable, declining from 100% to 68.9%. Furthermore,
there was a considerable loss of the high copy plasmids
within the HP, HO and E strains. Only 2.9% and 7.5% of
CFUs corresponding to the HP and E strains containedlmonella-EGFP strains
P+HO(1) CP+ E(1) E + LP(1) VAX-1 +ACYC177
05.9 ± 7.4 65.7 ± 2.5 68.3 ± 9.9 56.7 ± 6.6
ive double-recombinant strains (p < 0.01); Strains marked with (1) or (2)
ctive single-recombinant parental strains. (1) p < 0.01; (2) p < 0.05.
Table 4 Stability of antibiotic markers in six single-
recombinant Salmonella-EGFP strains
Strain Origin Detection rate for
antibiotic marker (%)
HP pUC 88.9
LP p15A 100.0
CP Chromsome-based 100.0
HO pUC 100.0
CO Chromsome-based 100.0
E pUC 100.0
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mid in the HO strain declined to very low levels that
could not be accurately calculated. The HP, HO and
E recombinant strains were significantly less stable
than the CP, CO and LP strains (p < 0.01). On day 7,
fecal bacterial cells from the six recombinant groups
decreased to very low levels, of around 103-104 cfu/g,
whilst the SL7207 group showed the best reserve, at
around 105 cfu/g (p < 0.01). Since construct stability
could not be accurately calculated at these low levels,
this data is not shown here. In summary, the CP
chromosome-based expression strain exhibited the
highest survival abilities in feces on day 1 and 3 after
inoculation. The high copy prokaryotic or eukaryotic
plasmids in the HP, HO and E strains appeared to be
less stable in fecal samples than the chromosome-
based expression cassettes in the CP and CO strains,
or the low copy plasmid in the LP strain.
The infection abilities of six single-recombinant Sal-
monella-EGFP strains were determined by detecting
their presence within the mouse spleens and mesenteric
lymph nodes, using the SL7207 strain as a control.
Figure 3B (1) & (2) shows the spleen infection results for
the recombinant strains. On day 1, spleen infection was
observed in the SL7207, LP, CP and CO groups. For the
SL7207 group, Salmonella was found in 66.7% of
mice spleens (4 out of 6 mice) with an average of 4 × 105
cfu/g. 83.3% of mice (5 out of 6 mice) in the LP group
were infected with Salmonella, with an average of
4 × 105 cfu/g. The detection rate for the low copy plas-
mid was 100.0%. For the CP and CO groups, the spleen
infection rates were 66.7% (4 out of 6 mice) and 50.0%Table 5 Stability of antibiotic markers in the five double-reco
Strains Origin 1 Detection rate for
antibiotic marker 1 (%)
O
CP+HP Chromosome-based 100.0
CP+ LP Chromosome-based 100.0
CP+HO Chromosome-based 100.0
CP+ E Chromosome-based 100.0
E+ LP pUC 50.0(3 out of 6 mice); with an average of 2 × 105 cfu/g and
8 × 104 cfu/g, respectively. Their chromosome-based
expression cassettes showed good stabilities, with detec-
tion rates of 96.9% and 100.0%, respectively. However,
no Salmonella infection could be detected for the HP,
HO and E strains, which contained the high copy pro-
karyotic or eukaryotic plasmids. On day 3, the spleen
infection levels for the recombinant strains had signifi-
cantly declined; however, the spleen infection rate in the
SL7207 group increased to 100.0% (6 out of 6 mice) with
an average of 2 × 105 cfu/g. Only 16.7% of mice (1 out of
6 mice) in the HP and CP groups had Salmonella infec-
tions in their spleen; with 1 × 103 cfu/g and 9 × 103 cfu/g,
respectively. The construct detection rate in HP group
was 0, while that in the CP group was 100.0%. For the
LP group, the spleen infection rate declined to 50%
(3 out of 6 mice) with an average of 4 × 104 cfu/g. The
low copy plasmid stability also declined to 30.0%. Even
so, the spleen infection rate for the LP group was still
higher than those for the HO, CO and E groups; for
which no infection was observed. On day 7, the spleen
infection rate in the SL7207 administration group was
still 100.0%, with an average of 7 × 105 cfu/g. For the HP
and HO groups, 83.3% of mice spleens (5 out of 6 mice)
tested positive for Salmonella infection, with an average
3 × 103 of cfu/g. However, no high copy plasmids could
be detected in cells of either of these two strains. For the
CO and E strains, only 16.7% of mice (1 out of 6 mice)
had spleens infected with Salmonella cells, with 3 × 105
cfu/g and 3 × 103 cfu/g, respectively. The stability of the
chromosome-based expression cassette within the CO
strain remained at 100.0%, but no pEGFP plasmid could
be isolated in the E group. Taken together, the results
showed that all six of the recombinant Salmonella-EGFP
strains could infect the spleen, but at different time
points. The spleen infection rates for the recombinant
strains were noticeably lower than those for the SL7207
group on day 3 and day 7. On day one, the LP low copy
plasmid strain, and the CP and CO strains containing
the chromosome-based expression cassettes had higher
spleen infection rates with good stability, compared to
the HP, HO and E strains containing high copy prokary-
otic or eukaryotic plasmids. Even though infection was
observed, the strains containing high copy prokaryoticmbinant Salmonella-EGFP strains
rigin 2 Detection rate for
antibiotic marker 2 (%)
Combined detection rate
for antibiotic markers (%)
pUC 0.8 0.8
p15A 100 100.0
pUC 60.0 60.0
pUC 100.0 100.0
p15A 100.0 50.0
Figure 3 In vivo survival, infection ability and construct stability of six single-recombinant Salmonella-EGFP strains. (A) Survival ability
and construct stability of the six single-recombinant Salmonella-EGFP strains in mice feces. A (1) CFU results for the six single-recombinant
strains in mice feces, on days 1, 3 and 7 after oral inoculation. Each bar in the graph represents the mean CFU/g of mice fecal samples
randomly collected from six mice in each group. Error bars show the standard deviation. ** indicates that the mean CFU/g was significantly
different from those of other strains (P< 0.01). The SL7207 strain was treated identically as a control. A (2) Construct retention rates for the six
single-recombinant strains in mice feces on days 1, 3 and 7 after inoculation. ** indicates that the mean of the construct retention rate in this
group was significantly different from those of the other strains (P< 0.01). (B) and (C) show the infection ability and construct stability results for
the six single-recombinant Salmonella-EGFP strains in mice spleen (B) and mesenteric lymph nodes (C). B (1) and C (1) show the CFU results
in mice spleen and mesenteric lymph nodes on days 1, 3 and 7 after inoculation, respectively. Each ● represents one mouse. Red lines
indicate the average CFU/g for each strain. The SL7207 strain was used as a control. B (2) and C (2) show the construct retention rates for the six
single-recombinant strains in mice spleen and mesenteric lymph nodes on days 1, 3 and 7 after inoculation, respectively. In A (2), B (2) and C (2),
each percentage is the mean construct detection rate based on six mice samples in each group. N/A represents the construct detection rate
could not be accurately calculated at this time point.
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on day 7.
The mesenteric lymph node infection results for the
recombinant strains are shown in Figure 3C (1) & (2).
On day 1, Salmonella infections were observed in the
SL7207, LP, CP, HO and CO groups; while no infection
was detected in the HP and E groups. Only 16.7% mice
(1 out of 6 mice) in the SL7207 and CO groups had
Salmonella infection in their lymph nodes, with levels of
1 × 104 cfu/g and 9 × 103 cfu/g, respectively. The detec-
tion rate for the chromosome-based expression cassette
within the CO strain was 100.0%. In the LP group, the
lymph node infection rate was 33.3% (2 out of 6 mice),
with an average of 2 × 103 cfu/g. For the CP and HO
groups, 50.0% of the lymph nodes (3 out of 6 mice)
tested positive for Salmonella infection, with an average
of 4 × 103 cfu/g and 2 × 104 cfu/g, respectively. The sta-
bility of the EGFP expression cassettes in the LP, CP and
HO groups were 92.9%, 100.0% and 73.3%, respectively.
On day 3, 33.3% of mice (2 out of 6) in the SL7207 and
LP groups had lymph node infections, with an average
of 2 × 103 cfu/g and 5 × 103 cfu/g, respectively. The
detection rate for low copy plasmids in the LP strain
was 75%. In the HP group, only 16.7% of mice (1 out of
6 mice) tested positive for Salmonella infection, with an
average of 3 × 103 cfu/g; however, no pHP plasmid could
be isolated. For the other four groups (CP, HO, CO and
E), no Salmonella infection was detected in the lymph
nodes. On day 7, the lymph node infection rates in the
SL7207 and HP groups were 33.3% (2 out of 6 mice)
with an average of 8 × 104 cfu/g and 2 × 103 cfu/g,
respectively. The detection rate for the high copy plas-
mid pHP was only 5.0%. For the CO group, 16.7% mice
(1 out of 6 mice) tested positive for Salmonella infection
in the lymph nodes, with average levels of 7 × 104 cfu/g.
The stability of the chromosome-based expression cas-
sette within the CO strain was 85.7%. Furthermore, the
infection rate for the E group increased to 66.7%, with
average counts of 1 × 103 cfu/g. However, the detection
rate for the high copy plasmid pEGFP was only 25.0%.
Considering these results as a whole, all the recombinant
strains were able to infect the mice mesenteric lymph
nodes at different time points; however, very few high
copy plasmids could be detected in the plasmid-based
recombinant strains on day 7.
In vivo immune response to recombinant Salmonella-
EGFP strains
EGFP-specific IgG responses in infected mouse sera
In order to compare the humoral immune responses
mounted against eleven recombinant Salmonella-EGFP
strains, ELISA assays were performed to test the anti-
EGFP IgG responses using blood sera of infected mice
on the 7th, 28th and 42th day after immunization.Results (Figure 4A) indicated that anti-EGFP IgG
responses of mice immunized with six single-
recombinant Salmonella-EGFP strains were very weak
on the 7th day after immunization. Only two mice, from
the LP and E groups respectively, had a 1:500 anti-EGFP
IgG titer. After receiving boosts on day 21 and 35, the
anti-EGFP IgG responses in the mice were greatly
increased. In the cytoplasmic expression group (HP, LP
and CP), 50.0% of mice (3 of the 6 mice) in the HP sub-
group had elevated anti-EGFP IgG responses. The aver-
age titers were around 1:21,000 on days 28 and 42.
100.0% of mice (all 9 mice) in the LP subgroup had
strong anti-EGFP IgG responses, and the highest titer
reached 1:200,000. The average titers were 1:47,000 on
day 28, and 1:65,000 on day 42. Notably, no response
could be detected in the CP subgroup even after two
boosts. In the membrane-based expression group, the
response rate for anti-EGFP IgG in the HO subgroup
was 44.4% (4 out of 9 mice) with an average titer of
1:390 on day 28, and 55.6% (5 out of 9 mice) with an
average titer 1:500 on day 42. Only 12.5% of mice (1 of 8
mice) in the CO subgroup had an anti-EGFP IgG re-
sponse, with a titer of 1:100 on day 28, and 1:500 on day
42. In the eukaryotic expression plasmid group, only
20.0% of mice (1 of 5 mice) responded, having a 1:10,000
anti-EGFP IgG titer on day 28, and a 1: 25,000 titer on
day 42. Collectively, based on the response rates, anti-
EGFP IgG response of strains containing either high or
low-copy prokaryotic expression plasmids were much
better than those containing a chromosome-based ex-
pression cassette or an eukaryotic expression plasmid;
especially the LP strain, which had significantly higher
average anti-EGFP IgG titers on day 42 (p < 0.05).
Humoral immune response assays were also per-
formed for the five double-recombinant Salmonella-
EGFP strains, to investigate whether these two-gene
constructs were capable of inducing stronger B cell
responses. The results from analogous sets of ELISA
experiments are shown in Figure 4B. Anti-EGFP IgG
responses in all five mice groups were very weak on 7th
day after immunization. Only 14.3% of mice (1 of 7
mice) in the CP +HP group and 16.7% of mice (1 out
of 6 mice) in the E + LP group generated a humoral
response, with titres of 1:100 and 1:1,000, respectively.
After two boosts on day 21 and 35, the response rate for
anti-EGFP IgG in each group had increased. 28.6% of
mice (2 of 7 mice) in the CP +HP group had anti-EGFP
IgG responses, with average titers of 1:1,400 on day 28,
and 1:1,500 on day 42. In the CP+LP group, 60.0% of
mice (3 out of 5 mice) had anti-EGFP IgG responses,
with average titers of 1:700 on day 28, and 1:2,500
on day 42. For the CP+HO strain, only 16.7% of
mice (1 mouse out of 6) had developed a response by
day 28; and by day 42, 33.3% (2 of 6 mice) had mounted
Figure 4 In vivo immune response against recombinant Salmonella-EGFP strains. The eleven recombinant Salmonella-EGFP strains were
respectively administrated to one of eleven groups of mice (5–10 mice for each group), with an additional group of non-infected mice kept as a
negative control. For each group, 1 × 1011 bacteria were used to prime each mouse for 3 days, and boost on day 21 and 35, by oral gavage. (A)
and (B) summarize the ELISA results showing the EGFP-specific IgG responses raised by the six single-recombinant Salmonella strains (A) and the
five double-recombinant Salmonella strains (B). ELISA assays were performed using mice sera collected on day 7, 28 and 42. * underneath the LP
strain in (A) indicates the mean ELISA titer raised by LP strain is significantly higher than those of other strain, as determined by One-Way ANOVA
(P< 0.05). (C) and (D) summarize the mice T cell anti-EGFP IFN-γ responses raised by the six single-recombinant Salmonella strains (C), and the five
double-recombinant Salmonella strains (D), using mice splenocytes collected on day 42. The ratio of spot numbers counted for the immunized
mice, to those counted for non-infected mice, were used to evaluate the anti-EGFP IFN-γ response. * underneath the CP and E strain in (C)
indicates the mean ELISpot ratios raised by CP and E strain were significantly higher than those of strains with high copy plasmids HP and HO;
* underneath the CP+ LP, CP + E and E+ LP strains in (D) indicates the mean ELISpot ratios raised by these strains were significantly lower than
their relative single parental strains, as determined by One-Way ANOVA (P< 0.05). Each ▲ represents one mouse. In (A) and (B), red lines indicate
the average titers for each strain. In (C) and (D), red lines indicate the average ratios for each strain.
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1:330. In the E + LP group, 33.3% of mice (2 out of 6
mice) developed anti-EGFP IgG responses, with average
titers of 1:17,000 on day 28; and 50.0% of mice (3 out of
6 mice) generated anti-EGFP IgG responses, with aver-
age titers of 1:35,000 on day 42. Notably, no response
could be detected in the CP+E group even after two
boosts. In brief summary, up to day 42, the humoral
response rates against the five double-recombinant
Salmonella-EGFP strains did not increase as was initially
expected. They were lower than the humoral response
rates observed for the respective single-recombinant
parental strains.Interferon-gamma (IFN-γ) responses to recombinant
Salmonella-EGFP strains
The T cell anti-EGFP IFN-γ responses against the eleven
recombinant Salmonella-EGFP strains were also deter-
mined within immunized mice. An equally sized group
of uninfected mice was included as a negative control.
The anti-EGFP IFN-γ responses were evaluated by
determining the ratio of ELISpot numbers counted for
the respective groups of immunized mice, divided by the
numbers counted for the control mice.
Figure 4C summarizes the ELISpot results obtained
for the six single-recombinant Salmonella-EGFP strains.
For the cytoplasmic expression group, the average ratios
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14.05, respectively. For the membrane expression group
(HO and CO), the CO subgroup had an average ratio
of 6.39, whilst a ratio of 0.92 was obtained for the
HO subgroup. The eukaryotic expression plasmid strain
(E) generated anti-EGFP IFN-γ responses with an aver-
age ratio of 16.55. Comparing the average ratios
obtained for the six recombinant strains, the strains con-
taining the eukaryotic expression plasmid (E) or the
chromosome-based expression cassette (CP) were cap-
able of inducing stronger anti-EGFP IFN-γ responses
than strains containing high-copy prokaryotic plasmids
(HP and HO) (p < 0.05). Interestingly, this general trend
is almost the opposite of that noted for the humoral
immune responses.
The anti-EGFP IFN-γ responses raised by the five
double-recombinant Salmonella-EGFP strains were also
evaluated, to investigate whether strains containing two
EGFP expression cassettes induced stronger T cell
responses than the corresponding single-recombinant
strains. As shown in Figure 4D, when CP was combined
with HP, LP, HO, or E, the average ratios of anti-EGFP
IFN-γ responses in mice were 5.33, 1.61, 9.90 and 2.87,
respectively. The average ratio of anti-EGFP IFN-γ
responses for the E + LP immunized mice versus the
control set was 4.95. In summary, the T cell responses
against the five double-recombinant Salmonella-EGFP
strains had not been enhanced as was initially expected.
Responses against several strains, such as CP +LP,
CP +E and E+ LP, were significantly lower than the re-
spective single-recombinant parental strains CP and E
(p < 0.05).
Construction and expression analysis of two recombinant
Salmonella-HA strains
In the first set of experiments, EGFP was used as a
model antigen to study and compare the immunogenic
potency of various recombinant Salmonella strains,
since previous studies have shown this protein to be
highly expressed in a soluble form within Salmonella
[20-22]. However, many other heterologous antigens, such
as viral proteins, may not be readily expressed in Salmonella
in a soluble form, due to factors such as codon bias, amino
acid composition or protein stability. Therefore, we chose
the HA epitope (91aa-261aa) from the avian influenza
H5N1 virus as a second model antigen. Considering the
codon bias between Salmonella and influenza virus, the
gene sequence encoding the HA fragment (HAOP) was
first codon optimized for expression within Salmonella,
and prepared synthetically by a commercial supplier
(GenScript). The HAOP fragment was subcloned into sets
of plasmids analogous to those used for the EGFP gene, in
order to construct analogous expression systems within
the parental Salmonella SL7207 strain.For cytoplasmic expression, HAOP was subcloned into
the pBSK-derived plasmid (pHP), placing it under the
control of the prosseA promoter (plasmid pHAOP). For
outer membrane expression, HAOP was subcloned into
the pHO plasmid to generate pO-HAOP. These two
constructs were separately transformed into SL7207, to
create a cytoplasmic HA expression strain of Salmonella
(C-HAOP) as well as an outer-membrane HA expression
strain of Salmonella (O-HAOP). The expression of
HAOP in these two recombinant strains was then con-
firmed by SDS-PAGE and Western blot analysis. As may
be seen in Figure 5A, HAOP was highly expressed
within the C-HAOP strain, being present almost exclu-
sively in the pellet fraction after cell lysis. This indicates
that it may be predominantly localized within insoluble
inclusion bodies in the cell cytoplasm. For the strain O-
HAOP, Western blot analysis of cell-membrane extracts
demonstrated that the expressed HAOP was associated
with the outer membrane (Figure 5B).In vivo immune response to recombinant Salmonella-HA
strains
Humoral immune response
HA-specific IgG responses in infected mouse sera
The humoral immune responses in mice infected with
the C-HAOP and O-HAOP strains were investigated
using ELISA assays analogous to those performed for
the EGFP antigen. We evaluated the anti-HA IgG levels
present in blood sera taken from mice infected with C-
HAOP and O-HAOP on the 7th, 28th and 42th day after
initial immunization. ELISA results suggested that the
C-HAOP strain could not elicit an anti-HA IgG re-
sponse, even after two boosts; giving readings identical
to the HO (EGFP) negative control strain (data not
shown). Results from ELISA analyses of the mice
infected with the O-HAOP strain (Figure 5C), revealed
that only 10.0% mice (1 out of 10 mice) had a 1: 1000
anti-H5 IgG titer on day 7. After the first boost, 30.0%
mice (3 out of 10 mice) had anti-H5 IgG responses with
titers of 1:1000, 1:500 and 1:50 (average 1:160) on day
28. After the second boost, the 30.0% mice (3 out of 10
mice) had increased anti-H5 IgG responses; two mice
having titers of 1:1000, and one with a titer of 1:500
(average titer of 1:250) on day 42. By day 42, O-HAOP
strain exhibited better humoral immunogenicity (includ-
ing response rate and anti-HA IgG titer) than C-HAOP
strain (p < 0.05).Hemagglutination Inhibition Assays (HIA) HIA tests
were performed using blood sera from mice infected
with O-HAOP strain on the 42nd day (i.e. after 3 identi-
cal immunizations: one prime and two boosts; same
schedule as above). Blood sera from non-infected mice,
Figure 5 Analysis of HA-antigen expression and in vivo immune response for recombinant Salmonella-HA strains. (A) Expression analysis
of the HAOP antigen in the C-HAOP strain using SDS-PAGE with Commassie Blue staining and Western blot. SL7207 was used as negative
control. (B) Western blot analysis of HAOP expression in the O-HAOP strain, using the HO strain as the negative control. (C) Results from ELISA
experiments showing HA-specific IgG response raised by the O-HAOP strain using the HO strain as a negative control. 10 mice were used for
each group. 1 × 1011 bacteria were used to prime each mouse for 3 days, and two boosts were given on day 21 and 35; all by oral gavage.
Blood sera from infected mice were collected on days 7, 28 and 42 for ELISA analysis. * underneath Day 42 indicates that the mean ELISA titer
raised by the O-HAOP strain was significantly higher than that of the -HAOP strain (P< 0.05). (D) Results from HIA using blood sera taken from
mice infected with O-HAOP strain on day 42. Blood sera from non-infected mice, and mice infected with the HO strain (taken on day 42) were
also used a controls. * underneath O-HAOP indicates the mean HIA titer raised by O-HAOP strain was significantly different from those of HO
and No-infection groups (P< 0.05). (E) T cell anti-HA IFN-γ responses provoked by the O-HAOP and C-HAOP strains, using the HO strain as a
negative control. Asterisks indicate that the average ELISpot ratios provoked by O-HAOP were significantly different to those provoked by HO
or C-HAOP (P< 0.05). In (C), (D) and (E), each ▲ represents one mouse. Red lines indicate the average titers in (C) and (D), and the average
ELISpot ratios in (E).
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(EGFP) strain were used as negative controls. Results
(Figure 5D) indicated that sera taken from 50.0%
O-HAOP-infected mice (5 out of 10 mice) con-
tained neutralization antibodies with titers ranging
from 1:16 to 1:128 (average titer of 1:30). The HIA
titers within the O-HAOP-infected mice weresignificantly different to those obtained for the non-
infected group (p < 0.05).
Interferon-gamma (IFN-γ) responses to recombinant
Salmonella-HA strains As performed for the Salmonella-
EGFP strains, T cell anti-HA IFN-γ responses raised against
the two recombinant Salmonella-HA strains (C-HAOP
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infected mice as well as HO-infected mice were used as
negative controls.
Analogous to before, the anti-HA IFN-γ responses
were evaluated by determining the ratio of ELISpot
numbers counted for the C-HAOP, O-HAOP or HO
infected mice, divided by the number counted for the
non-infected control set (Figure 5E). It was found that
the C-HAOP strain could not induce an anti-HA IFN-γ
response, with an average ratio of 0.91 obtained, versus
0.69 determined for the HO-infected group. However,
the O-HAOP strain elicited a better anti-HA IFN-γ
response comparing to the HO and C-HAOP groups
(p < 0.05), yielding an average ratio of 2.56.
Discussion
B cell responses and soluble antigen expression levels
The use of recombinant Salmonella strains as live atte-
nuated vaccines has been attracting increasing interest
over recent years, due to the low cost and relative ease
by which they may be produced on a large scale. [23-25].
Although numerous Salmonella vaccine systems have
been developed, relatively little work has been carried
out to systematically investigate which approaches or
construction methods reproducibly produce recombin-
ant strains with the highest immunogenicity levels. Here,
we used EGFP as a model antigen to study the relation-
ship between immunogenicity and the use of different
antigen expression systems in Salmonella. Six recombin-
ant strains, including three cytoplasmic expression
strains (HP, LP and CP); two outer-membrane expres-
sion strains (HO, CO) and one eukaryotic expression
plasmid (strain E), were constructed. Several different
pairs of EGFP-expression systems were combined, to
produce five additional ‘double-recombinant’ strains.
The antigen expression levels; in vitro and in vivo
growth and infection abilities; and the immunogenic
properties of these single and double-recombinant
strains in mice; were systematically investigated, in order
to evaluate their respective advantages, and to identify
deleterious or synergistic effects.
Within the set of three single-recombinant strains
designed for cytoplasmic expression of antigen protein,
the high copy plasmid pHP produced the highest
amounts of EGFP within the HP cells in vitro
(Figure 2B); resulting in relatively strong B cell responses
(anti-EGFP IgG response rate, Figure 4A), even though
the plasmid itself did not exhibit good stability in vitro
and in vivo (Table 4 and Figure 3). Although the EGFP
expression levels in the LP strain (containing the low-
copy pLP plasmid) were lower than those in the HP
strain, LP elicited a better B cell response, which is prob-
ably due to high EGFP expression and improved plasmid
stability in vitro and in vivo. The CP strain, whichcontains a (single-copy) chromosome-based expression
cassette, produced lower levels of EGFP expression than
the HP and LP strains, and induced a weaker B cell re-
sponse rate than these two strains. Out of the two
single-recombinant strains designed for outer membrane
expression, the HO strain, which harbors the high copy
number pHO plasmid, expressed higher levels of EGFP
than the chromosome-based CO strain in vitro, and also
elicited better B cell response rate. The EGFP expression
levels in the HO strain were lower than those in HP or
LP, the high copy plasmid pHO showed poor in vivo sta-
bility (as did pHP), and it also induced a weaker B cell
response than the LP strain. The B cell response rate
against the E strain, which harbors a eukaryotic expres-
sion plasmid, were weaker than those raised by the HP,
LP and HO strains; most likely because the EGFP cannot
be expressed until pEGFP has entered a host cell. In
addition, the eukaryotic plasmid expression levels may
not be as high as those generated by Salmonella strains
containing high or low copy prokaryotic plasmids.
Taken together, these findings suggest the strength of
the humoral immunity responses in mice infected with
recombinant Salmonella vaccines were positively corre-
lated to antigen expression levels and plasmid stability.
Therefore, maintaining high and stable antigen expres-
sion levels in recombinant Salmonella strains is of
key importance for eliciting a strong B cell response.
Furthermore, our results indicate that strains contain-
ing low copy prokaryotic plasmids are capable of
generating highest B cell responses with relative high
antigen expression level and improved stability over
high-copy plasmids.
During previous efforts to develop live recombinant
Salmonella oral vaccines, the expression of heterologous
antigens within Salmonella cells was achieved mainly
through the use of multi-copy prokaryotic plasmids
which contain the antigen of interest under the control
of a prokaryotic promoter. Plasmids with various copy
numbers have been used [26,27]. In several cases, such
as the construction of live attenuated Salmonella oral
vaccines against Streptococcus pneumonia, the H5N1
virus or hepatitis B virus; the antigens of interest
expressed from high copy prokaryotic plasmids were
able to induce strong immune responses, especially
humoral responses [7-9]. However, many of these vac-
cine strains had either negligible or fairly low immuno-
genicity, due to the instability of the high copy plasmid,
or toxic effects induced by the unregulated high-level
expression of these heterologous antigens [28-30]. Plas-
mids may be stably maintained in Salmonella cells dur-
ing in vitro growth via the use of the appropriate
antibiotic. However, the loss of high copy plasmids may
easily occur once Salmonella infects and grows inside
the host, due to the absence of antibiotic selection
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levels and decreased immunogenicity in vivo. Also, the
unregulated high level expression of antigen may create
a significant metabolic burden, or even toxicity for the
Salmonella cell, thus creating a selective pressure for
high copy plasmid segregation during cell division [27].
Here, the LP strain, which contained a low copy plasmid,
exhibited relatively high EGFP expression levels with
improved in vitro and in vivo stability, compared with
strains containing high copy plasmids. This strain
induced the highest levels of B cell immunogenicity
(Table 4 and Figures 2B, 3 and 4). This result is similar
to those reported in previous studies, which have found
that lowering the plasmid copy number results in
enhanced plasmid stability and a reduction in the
expression levels of heterologous antigens to non-toxic
levels [31-34].
Problems associated with plasmid instability and tox-
icity due to high-level antigen expression may be
circumvented through the use of a chromosome-based
expression strategy. In this and other studies, homolo-
gous recombination has been used to insert a heterol-
ogous antigen expression cassette into the Salmonella
chromosome, resulting in the creation of recombinant
strains with good in vitro and in vivo stabilities (Table 4
and Figure 3) [35,36]. However, as the heterologous gene
is present as a single copy per bacterium, the expression
levels may be too low to effectively induce a B cell
response. In this study, the poor B cell responses against
the chromosome-based expression strains CP and CO
were probably due to the low levels of EGFP expression
(Figures 2B and 4A). Similar findings have been pre-
viously reported. For example, during efforts to develop
a live Salmonella oral vaccine against fragment C of the
tetanus toxin (TetC), the recombination of TetC into the
aroC gene of S. typhimurium created a strain with good
stability; however low TetC expression levels resulted in
poor immunogenicity. One possible way to increase
expression levels would be to insert multiple copies of the
heterologous antigen genes into chromosome.
T cell responses, eukaryotic expression and colonization
with good stability
Salmonella has been used as a delivery vector for
eukaryotic plasmids for more than ten years [37-40]. In
these DNA vaccines, the plasmid encoding the target
antigen gene is placed under the control of a eukaryotic
promoter. Theoretically, Salmonella delivered-mucosal
DNA vaccines can invade the Peyer’s patches via M cells
in the intestinal mucosa, which contain many antigen-
presenting cells (APCs); such as macrophages and
dendritic cells [41]. Once phagocytized by the APCs, the
recombinant Salmonella cells would be lysed within the
phagosomes, releasing the eukaryotic plasmids into theAPCs. The APCs would then express the plasmid-
encoded antigen and present them to CD4+ or CD8+ T
cells in the Peyer’s patches or mesenteric lymph nodes
via MHC I and MHC II molecules. In addition, the
APCs may directly secrete the recombinant antigens
from the cells, so that B cells can recognize them via B
cell receptors (BCRs). This process induces further
mucosal, humoral or cellular immune responses against
the heterologous antigen [38,42-45]. Many studies
have found that Salmonella delivered DNA vaccines
were particularly good at generating T cell responses
against foreign antigens. In this project, we constructed
a Salmonella-DNA vaccine strain (strain E) which con-
tains a high copy eukaryotic plasmid (pEGFP). Using
Western blotting, we confirmed that pEGFP plasmid
delivered by the E strain could be used to successfully
express EGFP in mice intestinal mucosal sites on day 1
after inoculation (Figure 1E). Furthermore, we found that
this Salmonella-eukaryotic plasmid-based system could
induce better T cell responses than the Salmonella-high-
copy-prokaryotic plasmid-based systems (Figure 4C);
However, its antibody responses were quite low
(Figure 4A). Analogous findings have previously been
reported. In one comparative study, it was shown that
an oral Salmonella DNA vaccine strain encoding β-
galactosidase induced better T helper cell and CTL
responses than oral immunization with a Salmonella
strain containing a prokaryotic plasmid-encoded β-galac-
tosidase gene [38]. Similarly, oral immunization with the
surface protein from the hepatitis B virus delivered by a
Salmonella DNA vaccine elicited good T cell responses,
but its B cell responses were quite low [46]. Based
on our and others’ comparative analyses, we consider
it likely that the endogenously produced antigen deliv-
ered by the Salmonella-DNA vaccine may generate
immune responses mainly through the MHC I path-
way, thus resulting in higher T cell responses but lower
B cell responses.
ELISpot results suggested that a chromosome-based
expression system (CP strain) could also generate better
T cell responses than strains containing high copy pro-
karyotic plasmids. Furthermore, results from the in vivo
survival, infection ability and construct stability assays
(Figure 3), indicated that the CP strain had better
survival abilities and construct stability than strains con-
taining high copy plasmids. These findings indicated that
colonization with recombinant vaccine strains with good
construct stability is also an important factor for eliciting
strong T cell responses. This is most likely due to the
following reasons: T cell responses against Salmonella
infection can be effectively induced only after the
recombinant cells have invaded and proliferated within
the APCs [47]. However, after oral administration, the
bacterial cells would be in a low-nutrient environment
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also be subjected to acidic conditions within the GI
tract (even if this was partially negated by sodium bicar-
bonate lavage) as well as attack by the host immune
defenses. Consequently, non-integrating (episomal) plas-
mids would be lost fairly rapidly as observed in sur-
vival, infection ability and construct stability analyses
(Figure 3), thereby greatly reducing the abilities of the
bacterium to synthesize antigen protein in vivo.
Chromosome-based strains such as CP avoid this prob-
lem, albeit at the price of reduced antigen expression
levels. Even though the chromosome-based CO strain
showed in vivo stabilities equivalent to the CP strain,
its T cell responses were lower. It is possible that the
membrane-expressed EGFP significantly slowed the growth
rate of the CO strain (Table 2), resulting in poorer
in vivo survival and proliferation abilities (colonization
ability), compared to the CP strain (Figure 3A).
It is notable that for the various single-recombinant
strains, the general trend observed for the T cell
responses ran contrary to the trend observed for the
humoral immunity responses (described above). In this
regard, the properties of the LP strain are worth com-
menting on. Even though its induced T cell responses
were not as high as those elicited by the E and CP
strains, it could simultaneously induce both B cell and T
cell responses. It also exhibited better in vivo stability
than the strains containing high copy plasmids (Figure 3).
Consequently, if the aim was to develop a vaccine strain
capable of inducing both B cell and T cell responses,
then the use of a low copy cytoplasmic expression
system may be desirable.
Immunogenicity of strains encoding two EGFP
expression cassettes
Since the strains containing the high or low copy pro-
karyotic plasmids (HP, LP, HO) could induce better B
cell responses, while strains containing the eukaryotic
expression plasmid (E) or the chromosome-based
expression cassette (CP) elicited higher anti-EGFP IFN-γ
responses, we hypothesized that a combination of two
individual expression strategies may result in both stron-
ger B and T cell responses. Consequently, we created
five double-recombinant strains (CP+HP, CP +LP, CP +
HO, CP+E, E +LP). We used CP and E as the starting
strains for the construction of these five dual-expression
systems, using compatible plasmid replication origins
and orthogonal antibiotic resistance genes. The CP+HP,
CP +LP, CP +HO and E+LP strains were designed to
elicit both stronger B cell and T cell responses. The CP+
E strain was constructed to investigate whether it could
generate a T cell response that was higher than those
of the two individual strains. Contrary to our initial
expectations, both the humoral and T cell immuneresponses against these five double-recombinant strains
were not markedly improved, some of them were
obviously worse than their individual parent strains
(Figure 4). There are several possible reasons for this
lack of synergy: first, the combination increased the fre-
quency of plasmid loss. According to our in vitro plas-
mid stability studies (Table 5), we found that the
detection rates for pHP in the CP+HP strain, pHO in
the CP+HO strain and pEGFP in the E +LP strain were
0.8%, 60.0% and 50.0%, respectively. This suggested that
the high copy plasmids were more easily displaced in the
double-recombinant strains, resulting in a decrease in
EGFP expression levels (Figure 2B) and B cell responses
(Figure 4A and B). Second, antibiotic selection pressure
was increased. To maintain the plasmids, we used rela-
tively high concentrations of two antibiotics during the
subculturing procedures. However, the high-copy plas-
mids, containing pUC replication origins, were still fre-
quently lost from the cells. Upon losing the plasmid, the
relevant antibiotic will become toxic to the cell, resulting
in significantly decreased growth rates for the five
double-recombinant strains (Tables 2 and 3). It would
also cause an increase in ‘stress’ for the cell, resulting in
defects in replication and other growth-related effects;
which were manifested in the frequent formation of fila-
mentous cells (Figure 2A) [48-50]. Furthermore, even
though the high-copy plasmids were not lost from some
of the recombinant Salmonella strains in vitro; as was
noted for the HO, E and CP+E strains (Tables 4 and 5),
cell elongation was still observed (Figure 2A). This may
be due to the ‘metabolic burden’ [51-53] caused by the
active maintenance of multiple high copy plasmids
within the cell, leading to decreases in its overall
immunogenic properties.
Expression strategies for insoluble antigens in Salmonella
oral vaccine strains
As the expression abilities of Salmonella are relatively
similar to those of Escherichia coli, this prokaryotic sys-
tem may not be suitable for the expression of protein
antigens from viruses or higher eukaryotes [38]. Conse-
quently, when constructing a vaccine strain against a
virus such as avian influenza H5N1, several factors must
be taken into consideration. The first is codon bias; how-
ever this may be easily resolved by gene synthesis, using
the codons preferred by Salmonella. The second prob-
lem is the inability to express soluble antigen within the
cytoplasm, or to target it to the cell surface in a correctly
folded form. Many antigens from eukaryotic viruses,
such as the HA protein from H5N1, cannot be readily
expressed in a soluble form within the cytoplasm of Sal-
monella [8]. This type of situation can dramatically
decrease the B cell and T cell immune response within
the infected host. According to our in vivo immune
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could be detected when mice were immunized with the
C-HAOP strain, which was designed to cytoplasmically
express the HA antigen.
It has previously been reported that expressing the
antigen protein on the outer membrane of the engi-
neered bacterial cells may increase the immune response
[54], since this may increase the likelihood of recogni-
tion by the host immune system. To investigate this
issue, we targeted the EGFP protein for outer membrane
expression using the lpp-ompA outer membrane expres-
sion system. Analogous outer membrane expression
cassettes were located on a high-copy plasmid (HO
strain) and on the chromosome (CO strain). The B cell
responses (Figure 4A) against these two strains were
weaker than those obtained for the LP strain; and the T
cell responses (Figure 4C) against the HO strain were
lower than those obtained for the E and CP strains. This
may be because the total amounts of EGFP synthesized
and exported to the outer membrane were too low to
induce an effective B cell response (Figure 2B), or
because the in vivo stabilities of the high copy plasmids
were not sufficient to induce an effective T cell response
(Figure 3). However, this strategy proved somewhat
more successful for the HA antigen, which appears to be
largely present in insoluble inclusion bodies in the cyto-
plasm of Salmonella. We found that the use of the lpp-
ompA system, which is present in the O-HAOP strain,
resulted in the successful export of HA antigen to the
outer membrane fraction (Figure 5B). Furthermore,
results from ELISA, HIA and ELISpot assays indicated
this strain of Salmonella was capable of inducing better
HA-specific B cell and T cell responses than the corre-
sponding C-HAOP strain, which expresses the HA anti-
gen in the cytoplasm (Figure 5C, D and E). It is possible
that the use of the Lpp-OmpA system either helps the
HA protein fold into a soluble conformation, or results
in the export of increased amounts of HA protein, caus-
ing notable enhancements in immunogenicity.
Conclusions
In this study, we used EGFP and HAOP as model anti-
gens to systematically compare the immunogenic
potency of various recombinant Salmonella strains as
live, oral antigen-delivery vectors. Our results indicate
that if the antigen (such as EGFP) is soluble and easily
expressed in Salmonella, a low-copy plasmid-based
strategy should be employed, as it can provoke better B
cell responses and can also induce T cell responses. If a
T cell response is preferred, a eukaryotic plasmid, or
chromosome-based expression strategy may achieve bet-
ter results. For heterologous antigens that are likely to
be expressed in an insoluble form within Salmonella
(such as HA), an outer membrane-targeting approach isrecommended. In addition, we found that the combin-
ation of two expression strategies did not enhance the
immune response, and hence we caution against the use
of such an approach.
Methods
Ethics statement
All animal work was conducted according to relevant
national and international guidelines (Animal Research:
Reporting In Vivo Experiments guidelines). 6-8-week-old
female BALB/c mice purchased from the Laboratory
Animal Unit of the University of Hong Kong were used
for this study. This study was approved by the Com-
mittee on the Use of Live Animals in Teaching and
Research (CULATR) of The University of Hong Kong,
with the CULATR Number 2051–09.
Bacterial strains, media, chemicals, enzymes and plasmids
Escherichia coli strain DH10B (Invitrogen) was used
for all plasmid construction experiments. Attenuated
Salmonella enterica serovar Typhimurium aroA- strain
SL7207 was kindly provided by Dr. B.A.D. Stocker [55].
All bacteria were cultured in Luria-Bertani (LB) broth at
37°C. Minimal medium for target protein induction was
based on the N-salts recipe [56]. Antibiotics (Sigma) for
clone selection were used at the following final concen-
trations: ampicillin (Amp, 200 μg/ml), kanamycin (Km,
50 μg/ml) and chloramphenicol (Cm, 25 μg/ml). Restric-
tion endonucleases and ligase enzymes were purchased
from New England BioLabs (NEB). Taq polymerase (Pyr-
obest and Ex-taq) and the pMD18-T vector were from
Takara. Plasmid pSim6 was a gift from Dr. D.L. Court.
Plasmid pBluescript II SK (pBSK) was bought from Stra-
tagene. Other plasmids were from lab stocks.
Construction of recombinant Salmonella strains
expressing model antigens
Construction of ‘single-recombinant’ Salmonella-EGFP
strains
The compositions of six ‘single-recombinant’ Salmon-
ella-EGFP strains (i.e. strains containing a single episo-
mal or chromosomal copy of the EGFP gene) are listed
in Table 1. The primers used to construct the six ‘single-
recombinant’ Salmonella-EGFP strains are listed in
Table 6. The prosseA promoter was PCR amplified from
pathogenicity island 2 (SPI2) of SL7207 using the NotI-
prosseA-F and HindIII-prosseA-R primers; the EGFP
gene was PCR amplified from ploxp-cm-loxp with the
HindIII-EGFP-F and XhoI-Ter-EGFP-R primers; then
these prosseA and EGFP fragments were co-ligated into
vector pBSK via NotI and XhoI to create pHP.
The p15A origin was amplified from plasmid pACYC177
using primers p15A-F and p15A-R, and an EGFP expres-
sion cassette was amplified from pHP using primers
Table 6 Primers used in this study
Primer Name Primer Sequence (5’ to 3’)
NotI-prosseA-F ATTTGCGGCCGCAGAAGAGAACAACGGCAAGTTAC
HindIII-prosseA-R CCCAAGCTTACGATAGATAATTAACGTGC
XhoI-floxed-F CCGCTCGAGCCGATCATATTCAATAACCCT
XhoI-floxed-R CCGCTCGAGGACTAGTGAACCTCTTCGAGGG
HindIII-EGFP-F CCCAAGCTTAAGAAGGAGATATACATATGGTGAGCAAGGGCGAGGAGC
XhoI-Ter-EGFP-R CCGCTCGAGCGGCCGCAAAAAACCCCTCAAGACCCGTTTAGAGGCCCCAAGGGGTTATGCTAGTTACTTGTACAGCTCGTCCATGCC
p15A-F TATCACTTATTCAGGCGTAGCACC
p15A-R ATCGTATGGGGCTGACTTCA
ompA-F GGGAATTCCATATGAAAGCTACTAAACTGGTACTGGGCGCGGTAAACCCGTATGTTGGCTTTGAAATGGG
ompA-R CCGCTCGAGTTATGCGGCCGCGTTGTCCGGACGAGTGCCGATGGTGT
oEGFP-F ATTTGCGGCCGCAGTGAGCAAGGGCGAGGAGC
oEGFP-R CCGCTCGAGTTACTTGTACAGCTCGTCCATGCC
htrA-F CGCGTTATAAAATGAATCTGACGTACACAGCAATTTTGCGTTACCTGTTAATCGAGATTGAAACACAGGGTTTTCCCAGTCACGACGTT
htrA-R AGTTGTGGGGAGTTTCACAGAAAAGTGTTGCCCCCTTCCGTGGTGGAAGGGGGACAAAGGTGATTACTGGAGCGGATAACAATTTCACACAGG
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were directly ligated together to creat pLP.
The lpp-OmpA outer membrane expression cassette
was amplified from SL7207 using primers ompA-F and
ompA-R, and was ligated into the pMD18-T vector to
create plasmid pOmpA. pHO was constructed by ligat-
ing an EGFP cassette (amplified from ploxp-cm-loxp
using primers oEGFP-F and oEGFP-R) downstream of
lpp-OmpA in pOmpA via NotI and XhoI. Strains HP, LP,
HO and E were generated by transforming plasmids
pHP, pLP, pHO and pEGFP, respectively into SL7207 by
electroporation.
A loxp-Cm-loxp cassette was PCR amplified from
plasmid ploxp-Cm-loxp using primers XhoI-floxed-F
and XhoI-floxed-R [57], digested with XhoI, then ligated
into the XhoI site of plasmid pHP to create plasmid
pCP-cm. pCO-cm was generated by replacing the EGFP
gene in pHP with NdeI-lpp-OmpA-EGFP-XhoI and
XhoI-loxp-Cm-loxp-XhoI fragments. The linear dsDNA
fragments used to create the CP and CO chromosome-
based expression strains were respectively amplified from
pCP-cm and pCO-cm by PCR using a same pair of pri-
mers (htrA-F and htrA-R). Red recombineering was used
to construct the CP and CO strains, via transient expres-
sion of λ-Red genes from pSim6 in SL7207 according to
the method of Yu et al. [22,58]. Transformants were
selected by plating onto LB agar plates containing the
required antibiotics, incubating at 37°C overnight.Construction of the ‘double-recombinant’ Salmonella-EGFP
strains
The compositions of the five ‘double-recombinant’ Sal-
monella-EGFP strains (i.e. strains containing two individual
copies of the EGFP gene) are described in Table 1.Strains CP+HP, CP+LP, CP+HO and CP+E were gen-
erated by respectively electro-transforming plasmids
pHP, pLP, pHO or pEGFP into the CP strain. The LP+E
strain was generated by electro-transforming pEGFP into
the LP strain. Successful transformants were selected
on LB agar plates containing the appropriate antibiotics,
incubating at 37°C overnight.Construction of two recombinant Salmonella-HA strains
The sequence of the HA epitope (residues 91–261) from
the H5N1 virus (H5N1/A/Vietnam/1194/2004) was
codon-optimized for translation in Salmonella based on
sequence data from the NCBI-GenBank, and synthesized
by GenScript (Piscataway, USA). This synthetic codon-
optimized HA epitope gene (denoted HAOP) was cloned
between the NotI and XhoI sites of pHP (thereby
replacing the EGFP gene) to create pHAOP. pO-HAOP
was analogously generated by replacing the EGFP gene
of pHO with a NotI/XhoI-digested HAOP fragment.
Plasmids pHAOP and pO-HAOP were respectively electro-
transformed into SL7207 to generate a cytoplasmic-
expression HAOP Salmonella strain (denoted C-HAOP)
and a membrane-expression HAOP Salmonella strain
(denoted O-HAOP).Culture of recombinant Salmonella strains
In order to minimize plasmid loss, the recombinant Sal-
monella strains were freshly streaked from −80°C stocks
onto LB agar plates containing the required antibiotics
(Table 1) and incubated at 37°C overnight. Single col-
onies were inoculated into 30 ml liquid LB medium with
antibiotics and cultured at 37°C with shaking for
10 hours. The 10-hour bacterial cultures were expanded
(1:10) into fresh LB medium containing antibiotics,
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With the exception of the CP and CO strains, cells were
then collected by centrifugation (4,000 g, 4°C); washed
once with PBS; resuspended in PBS equal to the volume
of the original culture; then immediately used for
immunization or expression analysis. Further induction
was required for the CP and CO strains, using equal
volumes of N-salts medium. Prior to induction, freshly-
cultured CP or CO strains were collected by centrifuga-
tion (4,000 g, 4°C), then washed twice with N-salts
medium in equal volume of bacteria cultures. Cells were
then resuspended in N-salts medium containing the
appropriate antibiotics (equal to the original volume of
the bacterial culture), and incubated at 37°C for 24 hours
to induce protein expression. After 24 hours, cells
were collected for expression analysis or immunization
as above.
Expression analysis of recombinant Salmonella strains
Fluorescence microscopy
Fluorescence microscopy (Olympus BX51 microscope)
was used to analyze EGFP expression within the eleven
recombinant Salmonella strains. Freshly-cultured bacter-
ial cells (10 μl) were immobilized on 1% agarose pads on
glass slides, then visualized using a 60x oil-immersion
objective lens. Both bright-field and fluorescent field
(ex. 488 nm, em. 518 nm) images were captured (Spot
RT3 Digital Camera, Spot Advanced Software Version
4.6). Freshly cultured SL7207 cells were used as a nega-
tive control.
Fluorescence intensity assays
A fluorescence micro-plate reader (Varioskan Flash,
Thermo Fisher Scientific) was used to quantify EGFP
expression levels within freshly-cultured recombinant
Salmonella strains. 1 × 108 cells were resuspended in
100 μl PBS in 96-well plates (IWAKI, 96 well microplate
with flat bottom), and EGFP fluorescence intensity was
immediately recorded at room temperature (ex. 518 nm,
em. 518 nm; time resolution: 500 ms). Measurements
were performed in triplicate, and SL7207 was used as a
negative control.
SDS-PAGE and Western blot analysis
Sodium dodecyl sulfate-polyacrylamide gel electrophor-
esis (SDS-PAGE), followed by Western blot analysis was
performed to detect EGFP expression in the CO strain.
The in vitro and in vivo EGFP expression levels in E,
HAOP, C-HAOP and O-HAOP strains; were determined
using slightly-modified protocols for each strain.
CO strain: cells from 4 ml of induced bacterial culture
were collected and resuspended in 100 μl PBS + 50 μl of
loading buffer (60 mM Tris–HCl, pH 6.8, 25% glycerol,
2%SDS, 14.4 mM β-mercaptoethanol, 0.1% bromophenolblue) and boiled (10 minutes) to prepare lysates for ana-
lysis. GFP rabbit polyclonal IgG (Santa Cruz Biotechnol-
ogy) and goat anti-rabbit antibody conjugated with
horseradish peroxidase (Invitrogen), were used as the as
primary and secondary antibodies, respectively. SL7207
cells were also treated as above as the negative control.
E strain: in vitro and in vivo EGFP expression was
quantified by Western blot. The EGFP expression in the
eukaryotic cells was first detected in vitro by infecting
the Caco-2 human colon carcinoma cell line (American
Type Culture Collection) with the E strain. The Caco-2
human colon carcinoma cell line was cultured using
Dulbecco’s modified eagle’s medium (DMEM) (Invitro-
gen) with 20% fetal bovine serum (FBS) (Invitrogen) and
1% penicillin/streptomycin (P/S) (Invitrogen) in 24-well
plate (TPP, USA) with 5 × 105 cells per well at 37°C in
5% CO2. After cell confluence reached 90%, the medium
was removed and the cells were washed with PBS twice.
Then PBS-washed 1 × 107 CFU bacterial cells of E strain
in DMEM-20% FBS in the absence of antibiotics were
used to incubate with the Caco-2 cells. After 2.5 hours
incubation, the non-adherent bacteria were removed by
washing with PBS three times. DMEM with 20% FBS
was added to maintain the cells at 37°C in 5% CO2. Cell
samples were collected 12, 20 and 30 hours after infec-
tion, respectively. Caco-2 cell protein was extracted
using RIPA buffer (50 mM Tris–HCl pH 7.4, 150 mM
NaCl, 1 mM EDTA, 0.25% Deoxycholate, 1% NP40)
plus protease inhibitor cocktail tablets (Roche). Briefly,
cells were harvested and washed with cold PBS twice
(2500 x g, 5 min), then RIPA buffer containing protease
inhibitor was added to mix the cell pellet completely, and
this was incubated at 4°C for 15 minutes. The RIPA/cell
mixture was centrifuged (13000 x g, 1 min) and the
supernatant was collected for Western blot assay. The
protein quantities were measured using the BCA protein
assay kit (Thermo Fisher Scientific Inc). Equal amounts
of protein from the samples were loaded to detect EGFP
expression by Western blot using a GFP monoclonal
antibody (Santa Cruz Biotechnology) and a goat anti-
mouse secondary antibody conjugated with horseradish
peroxidase (DAKO). GAPDH detection was also per-
formed using an HRP conjugated antibody (Abnova).
The SL7207 strain was also treated as above as the nega-
tive control.
EGFP expression delivered by the E strain was also
investigated in the mouse intestine. 1 × 1011 of bacterial
cells of the E strain or the SL7207 strain re-suspended in
200 μl PBS, were orally administrated to 6-8-week-old
female BALB/c mice after neutralizing the gastric acid
(gavage with 100 μl of 3% sodium bicarbonate), respect-
ively. Intestinal mucosa samples from two groups of
mice were collected using heated glass slides on day 1,
3 and 7 after inoculation. Total proteins of intestinal
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inhibitor as mentioned before. Equal amounts of protein
samples quantified by BCA protein assay were used to
perform Western blot, to detect EGFP expression using
the same protocol mentioned above. GAPDH was also
detected as the internal control.
C-HAOP strain: total cell lysate (from 1× 109 bacterial
cells) was prepared as described above. For the cell-
fraction lysates, 1 × 109 cells were resuspended in 100 μl
PBS containing protease inhibitors (Roche, Complete
EDTA-Free), then sonicated (Sonics, model VCX750;
with ice cooling). After centrifugation (12,000 x g;
1 min; 4°C), the supernatant (ca. 90 μl) was decanted
and 50 μl of (x3) loading buffer added. The pellet was
resuspended in 100 μl of (x1) loading buffer. Samples
were similarly boiled (10 mins), prior to Western blot
analysis using rabbit polyclonal influenza A virus
hemagglutinin antibody (ab36565, Abcam) and goat
anti-rabbit antibody conjugated with horseradish perox-
idase (Invitrogen) as primary and secondary antibodies,
respectively. SL7207 cells were treated as above as nega-
tive control.
O-HAOP strain: 40 ml of freshly-cultured bacterial
cells were harvested by centrifugation (3,500 x g, 15
mins, 4°C), resuspended in 10 ml PBS containing prote-
ase inhibitors, then sonicated 4°C). The cell debris was
removed by centrifugation (3,500 x g, 10 mins, 4°C),
then the supernatant was ultra-centrifuged (100,000 x g,
60 mins, 4°C) to collect the total membrane fraction
(as the pellet). A portion of the membrane fraction
was resuspended in PBS containing 0.01 mM MgCl2
and 2% Triton X100, and then centrifuged (100,000 x g,
60 mins, 4°C). The inner membrane fraction was col-
lected as the supernatant; whilst the pellet, which con-
tains the outer membrane fraction, was resuspended in
1 ml PBS. The protein concentration of each fraction
was measured using the bicinchoninic acid (BCA) pro-
tein assay (Thermo Fisher). Each fraction was boiled
with loading buffer (as above) and analyzed by Western
blotting using rabbit polyclonal influenza A virus
hemagglutinin antibody and HRP-conjugated goat anti-
rabbit antibody as primary and secondary antibodies,
respectively. The membrane fraction from the HO strain
was used as a negative control.
Morphological observation of recombinant Salmonella-
EGFP strains
Microscopic images of SL7207 and the various recom-
binant Salmonella-EGFP strains were captured using
light microscopy (Olympus BX51 microscope). Twenty
cells from each recombinant strain, as well as the
SL7207 control were randomly selected from the micro-
scopic images for cell length analysis using the Image J
software program [58]. The mean cell length for eachstrain was reported ± standard deviation and then com-
pared to the SL7207 control.
In vitro growth of recombinant Salmonella-EGFP strains
and stability of EGFP expression constructs under
antibiotic pressure
To assess the growth of the six single-recombinant and
five double-recombinant Salmonella-EGFP strains
in vitro, the doubling times of these eleven recombinant
strains were measured in liquid LB broth with antibio-
tics. Apart from using SL7207 as a general negative con-
trol, the empty vectors: pBSK, pACYC177, pOmpA,
pVAX-1 were electro-transformed into SL7207 to
create strains: BSK, ACYC177, OmpA and VAX-1 as
the negative controls of HP, LP, HO, E strains, respect-
ively. The VAX-1 +ACYC177 strain was generated by
co-electrotransforming pACYC177 and pVAX-1 into
SL7207, as a negative control for the E + LP strain. 10-
hour bacterial cultures from each strain obtained using
the protocol described in Part 3 were diluted 1:100 into
fresh LB medium containing antibiotics. The diluted
cultures were then incubated at 37°C with shaking. Bac-
terial growth was measured spectrophotometrically
using OD600, at intervals of 30 mins. Four replicates
were performed for each strain, and the mean is
reported ± standard deviation.
The stability of the six single-recombinant and five
double-recombinant Salmonella-EGFP strains under
antibiotic selective pressure, prior to oral administration
were measured via colony forming unit (CFU) assay.
1 × 109 cells from each strain were collected and resus-
pended in 1 ml fresh LB. Six 1:10 serial dilutions were
performed, and 10 μl of each dilution was spread on LB
agar plates, or LB agar plates containing the appropriate
antibiotics as listed in Table 1. Colonies were counted
after incubation overnight at 37°C. Three replicates
were performed for each dilution, and the mean is
reported ± standard deviation.
In vivo survival and infection ability of six single-
recombinant Salmonella strains and stability of EGFP
expression constructs
In order to determine the survival and infection abilities
of the six single-recombinant Salmonella EGFP strains,
and the in vivo stabilities of the six EGFP expression
constructs, 1 × 1011 of freshly cultured bacterial cells
from each of the six strains resuspended in 200 μl PBS,
were separately orally administrated to 6-8-week-old
female BALB/c mice after neutralizing the gastric acid.
6 mice were grouped for each of the six strains, and one
group of mice immunized with SL7207 was kept identi-
cally as the negative control. Fecal, spleen and mesen-
teric lymph nodes samples were collected from each
group on days 1, 3 and 7 after administration for CFU
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and re-suspended in 9 × LB broth according to sample
weights. Then seven 1:10 serial dilutions were carried
out in a final volume 100 μl. 10 μl of each dilution was
spread on LB agar plates, or LB agar plates containing
the appropriate antibiotics as listed in Table 1. Enumer-
ation was performed after incubation overnight at 37°C.
Three replicates were performed for each dilution, and
the mean is reported ± standard deviation.
In vivo immune response assays
Animal immunization
6-8-week-old female BALB/c mice purchased from the
Laboratory Animal Unit of the University of Hong Kong
(CULATR 2051–09) were used for all in vivo immune
response tests. Identical batches of 1 × 1011 of PBS-
washed, freshly-cultured bacterial cells resuspended in
200 μl PBS were used for each immunization procedure
(prime and boost) for each strain. Immediately prior to
oral administration, each mouse was orally gavaged with
100 μl of 3% sodium bicarbonate to neutralize gastric
acid. Cells were administered by oral gavage; giving
two boosts on day 21 and day 35 after the initial
prime. Groups of 5–10 mice were used for each of
the 11 recombinant Salmonella-EGFP strains, and one
group of non-infected mice were kept identically as the
negative control. In analogous parallel experiments,
three further groups of 5–10 mice were orally immu-
nized with the C-HAOP, O-HAOP or HO (as control)
strains; with an additional group of non-infected mice
kept as a negative control.
Humoral immunity assays
ELISA
Enzyme-linked immunosorbent assays (ELISA) were
used to detect antigen-specific IgG response using mice
serum on day 7, 28 and 42. ELISA plates (Ni-NTA His-
SorbTM plate, QIAgen) were pre-coated with 100 ng
GFP (Millipore) or H5 antigen (H5N1, A/Vietnam/1203/
2004, Immune Technology Corp.) in 100 μl of PBS con-
taining 0.2% BSA, at 4°C overnight. The pre-coating so-
lution was removed, then unreacted sites were blocked
with 200 μl of PBS containing 1% BSA, incubating for 2
hours at room temperature. After removal of blocking
buffer, serial dilutions of mice serum in 100 μl of PBS
containing 0.2% BSA were added, then plates were incu-
bated at room temperature for 2 hours. Unbound serum
antibodies were washed-off with PBST (6 washes). Goat
anti-mouse IgG antibody conjugated with horseradish
peroxidase (Invitrogen, 20,000-fold dilution in 100 μl
of PBS containing 0.2% BSA) was added and plates
were incubated at room temperature for 1 hour. After
6 washes with PBST, 200 μl of TMB solution (Calbio-
chem) was added, and plates were incubated at roomtemperature until the appearance of a blue color. The
reaction was stopped by adding 50 μl of 2 M sulphuric acid,
then intensities were determined at 450 nm using a micro-
plate reader (Spectra Max 340, GrandTech Scientific).
Hemagglutination inhibition assay (HIA)
Hemagglutination inhibition assays (HIA) were per-
formed according to a standard protocol with minor
modifications [59]. Briefly, serial two-fold dilutions of O-
HAOP vaccinated mice serum (ranging from 1:8 to
1:256, in PBS; final volume of 25 μl;) were added to wells
of a microtiter plate, together with 25 μl of H5N1 virus
suspension (H5N1/A/Vietnam/1194/2004). Microplates
were incubated at room temperature for 30 minutes
with gentle shaking. 50 μl of chicken red blood cell sus-
pension was added to each well, and plates were incu-
bated at room temperature with gentle shaking until the
chicken red blood cell control (chicken red blood cell in
50 μl PBS) formed a button at the bottom of a well. The
HIA titer for each serum sample was defined as the
highest dilution of serum that could completely inhibit
hemagglutination. Sera from non-infected mice, as well
as those inoculated with the HO strain were used as
negative controls. Three replicates were performed for
each dilution.
ELISpot
ELISpot assays were used to detect the antigen-specific
mouse IFN-γ response as described in the Mabtech
manual of ELISpot kit. The ELISpot plate (Mabtech) was
first activated by adding 50 μl of 70% ethanol to each
well for 2 minutes, followed by washing 5 times with
200 μl sterile water. Wells were then pre-coated with
100 μl of 15 μg/ml anti-mouse IFN-γ antibody (AN18
Mabtech) diluted in sterile PBS, incubating at 4°C over-
night. Excess antibody was then removed by washing 5
times with 200 μl sterile water. Plates were incubated
with 200 μl of RPMI 1640 medium containing 10% fetal
bovine serum (FBS) for 30 minutes. During incubation,
spleens taken from day 42 mice were homogenized and
treated with red blood cell lysis buffer (10 mM KHCO3,
150 mM NH4Cl, 0.1 mM EDTA). The spleen cell homo-
genates were filtered (40 μm cell strainer, BD Falcon)
then centrifuged (1000 x g, 8 minutes, 4°C). Cell pellets
were suspended in RPMI 1640 medium containing 10%
FBS. 2 × 105 cells in 100 μl RPMI 1640 medium contain-
ing 10% FBS were added to each pre-coated well. For
each mice, 200 ng of H5 or GFP antigen and 100 anti-
mouse CD28 (BD Pharmingen) were added to triplicate
wells as sample stimulatory agents; 2 ng phorbol 12-
myristate 13-acetate (PMA, Sigma), 100 ng Ionomycin
calcium salt (INO, Sigma) and 100 ng anti-mouse CD28
were added into triplicate wells as the stimulatory agents
of positive control; Meanwhile, another triplicate wells
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Plates were then incubated at 37°C for 44 hours. Wells
were then washed 5 times with 200 μl PBS, and incu-
bated with 100 μl of 1 μg/ml detection antibody (R4-
6A2-biotin, Mabtech) in PBS-0.5% FBS for 2 hours at
room temperature. Unbound antibody was removed by
washing 5 times with 200 μl PBS, then plates were incu-
bated with 100 μl of 1000-fold diluted Streptavidin-HRP
in PBS+ 0.5% FBS for 1 hour at room temperature. After
washing 5 times with 200 μl PBS, 100 μl of TMB solu-
tion was added, and plates were allowed to develop at
room temperature until distinct spots emerged. Colour
development was stopped by washing extensively with
water. After allowing spots to dry at room temperature
in a fume hood, plates were analyzed using an ELISpot
reader (C.T.L. Analyzers, LLC).
Statistical analysis
Differences between the means of two experimental
groups were analyzed by the Student’s t-test. One-Way
ANOVA (SPSS 16.0, SPSS Inc., Chicago, USA) was per-
formed to compare the differences of multiple groups.
Results are presented as mean values ± standard error,
and at least three independent replicates were performed
for each condition.
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